Certolizumab Pegol
Indication
Crohn's disease
Black
Brand:
Cimzia®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Gastro-intestinal system
Background
Whilst there is evidence of efficacy in Crohns Disease from trials and retrospective observational studies of certolizumab, this evidence is insufficient to support their off-label use ahead of licensed and NICE-recommended agents, or following exhaustion of licensed and NICE-recommended agents.
Recommendation
LSCMMG Recommendation:
Black
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria
Supporting documents: